Validating a rapid method for pharmaceutical applications

Supported by:

16 May 2013


Validation of rapid methods continues to be an obstacle to greater adoption of these technologies. Some of the benefits of rapid methods are well articulated across industry literature, including the ability to release products much faster as well as intervene faster in the event of contamination in any part of the manufacturing process. Regulatory approval and the challenge of actually validating the rapid method for many applications continue to be viewed as stumbling blocks.

Keynote speakers

Silvia Fragoeiro, Team Leader – MSD Animal Health, Merck

Experiences in implementing and validating a rapid method

Silvia Fragoeiro - Rapid Method webinar

Silvia Fragoeiro of MSD will be speaking about her experiences with implementing a rapid method.  She recently co-authored an article in EPR on the implementation of a rapid method to improve the quality of polyclonal antibodies used for the quality control of antigens produced by MSD for vaccines.  She will be speaking about her experiences in implementing and validating a rapid method for this application.

Juan Gonzalez-Garzon, Applications Specialist Industry-Europe, BD

A flow cytometry based rapid method and the various applications that can be performed

Juan Gonzalez-Garzon - Rapid Method webinar

Juan has a B.Sc. degree in Pharmaceutical Sciences from the University Complutense in Madrid, specializing in Food Microbiology and Dietetic, with a dedicated internship in the clinical microbiology Laboratory at the Hospital Gregorio Marañón of Madrid. Juan currently works as the European Application Manager at BD Industrial Microbiology. This job role has responsibilities for the scientific support of traditional and rapid microbiology and support for alternative microbiology methods (Pre-Validation Studies on the BD FACSMicroCount™ and BD BACTEC FX) in the industrial pharmaceutical sector. Prior to that, Juan was working as Field Application specialist in BD providing scientific support for the clinical customers in BD Diagnostic Systems.

Dr. Michael Miller, President, Microbiology Consultants, LLC

Advantages and regulatory acceptance of RMMs within the industry

Dr Michael Miller - Rapid Method webinar

Dr. Michael J. Miller is an internationally recognised microbiologist and subject matter expert in pharmaceutical microbiology and the design, validation and implementation of rapid microbiological methods. He is currently the President of Microbiology Consultants, LLC. Over the course of 25 years, he has held numerous R&D, manufacturing, quality, and consulting and business development leadership roles at Johnson & Johnson, Eli Lilly and Company, Bausch & Lomb, and Pharmaceutical Systems, Inc. In his current role, Dr. Miller consults with multinational companies in providing technical, quality and regulatory solutions in support of RMMs, sterile and non-sterile pharmaceutical manufacturing, contamination control, isolator technology, validation and microbiological PAT. He also provides comprehensive training for his clients in the areas of rapid method validation and implementation.

Dr. Miller has authored more than 100 technical publications and presentations in the areas of rapid microbiological methods, PAT, ophthalmics, disinfection and sterilisation, is the editor of PDA’s Encyclopedia of Rapid Microbiological Methods, and is the owner of rapidmicromethods.com, a website dedicated to the advancement of rapid methods. He currently serves on the editorial board for European Pharmaceutical Review, is chairing the revision of PDA Technical Report #33: Evaluation, Validation and Implementation of New Microbiological Testing Methods, and routinely provides RMM training programs for the industry and professional organisations worldwide.

Supported by BD

BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures and support the management of diabetes. 
Find out more: www.bd.com

The rest of this content is restricted - login or subscribe free to access

Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • bi-monthly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here


Related organisations

18 responses to “Validating a rapid method for pharmaceutical applications”

  1. John Van der Werf says:

    This webinar looks interesting. Is it still possible to join?

  2. Jen says:

    What is the cost of the Webinar? My apologies if it is listed and I missed it- Thank you-

    • Matt Cheeseman says:

      Hi Jen,

      The webinar is completely free to attend.

      We hope you enjoy it!


  3. Kazi Tahsin Ahmed says:

    I’m very interested to attend this webinar meeting. Thanks

  4. Thanveer t says:

    Good to hear about the seminar conducting by bd. see u there. Thank you

  5. Look forward to not reinventing the wheel.

  6. I am looking forward to this webinar seminar. Thank you very much.

  7. Stefan Wennmalm says:

    It is not quite clear to me what Dr Miller will speak about, and the presentation of Dr Gonzalez-Garzon, on flow cytometry, actually sounded more fitting for me, but I will at least attend the start of the webinar of Dr Miller.

    with best regards,

    Stefan Wennmalm

    • Matt Cheeseman says:

      Hi Stefan,

      We are currently awaiting a synopsis of the topic Dr. Miller will be discussing. This page will be updated as soon as this is received.

      We very much hope you enjoy our webinar!


  8. I look forward to the webinar.
    It is very interesting.

  9. Arhs says:

    I’m very interested to attend this webinar meeting,this presentation will give us any certificate ???
    Thanks a lot

    • Matt Cheeseman says:

      Hi Arhs,

      Unfortunately this webinar will not give you a certificate, but it will provide you with practical information and examples of validating a rapid method in the pharmaceutical industry.

      We hope you will find this webinar useful!


  10. R J Shah says:

    This is a good webinar and may be also at a right time. Very recently during one of the presentations on current technologies, I gave a brief about RMM and was bombarded with many questions, some of which I could not respond to. These were pertaining to identification and detection of spores with this technology and how to validate the method. So, I hope the speakers will make an attempt to cover these points too, in case they have not addressed these in their presentation.

    With Regards,

    R J Shah

  11. Looking forward to this seminars and learn more from it.

  12. Luis Guido says:

    I am looking forward to attend this Webinar. Thanks.

  13. Matt Cheeseman says:

    Hi Christian, we’re very glad you’re interested in attending the webinar and we hope you enjoy it!

  14. Christian Sammartino says:

    I’m very interested to attend this webinar meeting. Thanks